
Daniel J Felmlee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1604948/publications.pdf Version: 2024-02-01



DANIEL | FELMIEE

#	Article	IF	CITATIONS
1	Infection with the hepatitis C virus causes viral genotype-specific differences in cholesterol metabolism and hepatic steatosis. Scientific Reports, 2022, 12, 5562.	1.6	8
2	Investigation of microbiome metabolites and mitochondrial function in non-alcoholic fatty liver disease. Journal of Hepatology, 2020, 73, S240.	1.8	0
3	Zooming in on liver zonation. Hepatology, 2018, 67, 784-787.	3.6	11
4	Lipid interactions influence hepatitis C virus susceptibility and resistance to infection. Clinical Liver Disease, 2017, 10, 17-20.	1.0	6
5	New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infectious Diseases, The, 2016, 16, 735-745.	4.6	41
6	A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses. Hepatology, 2016, 63, 35-48.	3.6	131
7	Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies. Gastroenterology, 2016, 150, 206-217.e4.	0.6	64
8	Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals. Viruses, 2015, 7, 6716-6729.	1.5	72
9	PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: Evidence for genotype-specific regulation of lipoprotein metabolism. Journal of Hepatology, 2015, 62, 763-770.	1.8	33
10	Syndecan 4 Is Involved in Mediating HCV Entry through Interaction with Lipoviral Particle-Associated Apolipoprotein E. PLoS ONE, 2014, 9, e95550.	1.1	64
11	Unraveling hepatitis C virus structure. Cell Research, 2014, 24, 385-386.	5.7	6
12	Omegaâ€3 fatty acids and/or fluvastatin in hepatitis C prior nonâ€responders to combination antiviral therapy – a pilot randomised clinical trial. Liver International, 2014, 34, 737-747.	1.9	12
13	Entry of hepatitis B and C viruses — recent progress and future impact. Current Opinion in Virology, 2014, 4, 58-65.	2.6	43
14	New tool for the study of hepatitis C virus genotype 3 and its associated liver disease biology. Hepatology, 2014, 60, 1806-1808.	3.6	0
15	Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency. Metabolic Brain Disease, 2014, 29, 625-634.	1.4	9
16	Hepatitis C virus co-opts innate immunity component for lipid droplet formation. Journal of Hepatology, 2013, 59, 1118-1120.	1.8	5
17	Hepatitis C Virus Entry. Current Topics in Microbiology and Immunology, 2013, 369, 87-112.	0.7	130
18	Hepatitis C virus vaccines – Progress and perspectives. Microbial Pathogenesis, 2013, 58, 66-72.	1.3	34

Daniel J Felmlee

#	ARTICLE	IF	CITATIONS
19	Interferon-lambda polymorphisms and hepatitis C virus clearance revisited. Hepatology, 2013, 58, 439-441.	3.6	8
20	Hepatitis C Virus, Cholesterol and Lipoproteins — Impact for the Viral Life Cycle and Pathogenesis of Liver Disease. Viruses, 2013, 5, 1292-1324.	1.5	126
21	Modeling the antiviral activity of ribavirin against hepatitis C virus in cell culture. Hepatology, 2013, 58, 1203-1206.	3.6	0
22	Neutralizing Antibodies and Pathogenesis of Hepatitis C Virus Infection. Viruses, 2012, 4, 2016-2030.	1.5	23
23	Reconstitution of the Entire Hepatitis C Virus Life Cycle in Nonhepatic Cells. Journal of Virology, 2012, 86, 11919-11925.	1.5	83
24	Cholesterol uptake and hepatitis C virus entry. Journal of Hepatology, 2012, 57, 215-217.	1.8	7
25	Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: Evidence for an association with interferon sensitivity. Journal of Hepatology, 2012, 57, 32-38.	1.8	35
26	HCV and the hepatic lipid pathway as a potential treatment target. Journal of Hepatology, 2011, 55, 1428-1440.	1.8	54
27	Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infection. Gut, 2011, 60, 680-687.	6.1	20
28	Intravascular Transfer Contributes to Postprandial Increase in Numbers of Very-Low-Density Hepatitis C Virus Particles. Gastroenterology, 2010, 139, 1774-1783.e6.	0.6	68
29	Low density Hepatitis C virus particles (lipoviral particles) associate with insulin resistance in genotype 1 infection. Atherosclerosis, 2010, 213, e4.	0.4	1
30	Hepatitis C Virus Induces Proteolytic Cleavage of Sterol Regulatory Element Binding Proteins and Stimulates Their Phosphorylation via Oxidative Stress. Journal of Virology, 2007, 81, 8122-8130.	1.5	240
31	Hepatitis C Virus Nonstructural Proteins Inhibit Apolipoprotein B100 Secretion. Journal of Biological Chemistry, 2005, 280, 39802-39808.	1.6	59